OakChart

Inventiva ADR

IVAHealthcare·Biotechnology·France·Small·NASD·Nov 11 • 3:59 PM ET

4.01+0.06 (1.52%)
2026-11-11 23:41 CET
Market cap
944.46 USD m
Revenue, TTM
0.06 USD m
Net income, TTM
-288.92 USD m
Free cash flow, TTM
-131.95 USD m
EPS diluted, TTM
-1.37
P/E
-
Compare

Price

IVA against its 20, 50 and 200-day averages
2050200beat
3.004.005.006.002.7M5.3MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26IVAclose 4.0120-day 3.6350-day 3.68200-day 4.774.0152w low

45.0% under the 52-week high of 7.29 on 26 Jan 2026. 52-week low 2.82 on 14 Oct 2026. Last 15 sessions, 25.8% high to low

Volume 1.13× normal · the line is the 50-bar volume average

Profile

IVA
52-week range, 27% of the way up
2.827.29

Inventiva SA is a clinical-stage biopharmaceutical company, which focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis, or NASH, and other diseases with significant unmet medical need. It owns an in-house drug-discovery platform that develops internal oncology and fibrosis discovery pipeline with approaches centered on transcription factors, epigenetics targets, and nuclear receptors. The company was founded by Pierre Broqua and Frederic Cren on October 27, 2011 and is headquartered in Daix, France.

Employees77
IPOJul 10, 2020
Beta0.73
ATR, 14d0.27
Rel volume1.13
Short float4.68%
Insider own7.56%
Inst own29.47%

Snapshot

6 groups

Valuation

Index-
Market Cap958.79M
Enterprise Value845.07M
Income-288.92M
Sales0.06M
Book/sh0.29
Cash/sh0.79
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees77
IPOJul 10, 2020

Ratios

P/E-
Forward P/E-
PEG-
P/S15979.85
P/B14.05
P/C5.05
P/FCF-
EV/EBITDA-
EV/Sales14084.52
Quick Ratio3.81
Current Ratio3.81
Debt/Eq1.13
LT Debt/Eq0.90
Option/ShortYes / Yes

Earnings

EPS (ttm)-1.37
EPS next Y-0.56
EPS next Q-0.16
EPS this Y68.36%
EPS next Y18.53%
EPS next 5Y53.16%
EPS past 3/5Y-15.85% -13.59%
Sales past 3/5Y-26.61% 64.18%
EPS Y/Y TTM66.37%
Sales Y/Y TTM-99.61%
EPS Q/Q-
Sales Q/Q-
EarningsSep 28 BMO
EPS/Sales Surpr.32.68% -99.21%

Ownership

Insider Own7.56%
Insider Trans0.00%
Inst Own29.47%
Inst Trans9.33%
ROA-116.32%
ROE-1022.99%
ROIC-224.94%
Gross Margin-5232.81%
Oper. Margin-307068.32%
Profit Margin-505545.60%
SMA2010.55%
SMA509.01%
SMA200-15.92%
Trades-

Technical

Shs Outstand239.10M
Shs Float221.02M
Short Float4.68%
Short Ratio4.94
Short Interest10.35M
52W High7.29 -44.99%
52W Low2.82 42.20%
Volatility7.61% 7.62%
ATR (14)0.27
RSI (14)60.15
Beta0.73
Rel Volume1.13
Avg Volume2.10M
Volume2,371,985

Performance

Perf Week3.62%
Perf Month39.72%
Perf Quarter-12.83%
Perf Half Y-27.62%
Perf YTD-13.76%
Perf Year3.62%
Perf 3Y8.67%
Perf 5Y-72.29%
Perf 10Y-
Recom1.00
Target Price14.64
Prev Close3.95
Price4.01
Change %1.52%

Analyst ratings

latest 10 of 19
DateActionAnalystRating changeTargetImplied
Jul 17, 2026InitiatedCCantor FitzgeraldOverweight
Mar 19, 2026InitiatedTTruistBuy$13+224.2%
Jan 28, 2026InitiatedBBarclaysOverweight$18+348.9%
Jan 12, 2026InitiatedLLeerink PartnersOutperform$12+199.3%
Jan 07, 2026ResumedUUBSBuy$12+199.3%
Nov 06, 2025InitiatedWWolfe ResearchOutperform$13+224.2%
Sep 03, 2025ResumedHH.C. WainwrightBuy$20+398.8%
Aug 27, 2025InitiatedPPiper SandlerOverweight$26+548.4%
Feb 21, 2025InitiatedTTD CowenBuy$10+149.4%
Nov 12, 2024InitiatedUUBSNeutral$3-25.2%

Peers

Mkt cap
TickerCompanyMkt cap
MDGLMadrigal Pharmaceuticals Inc10.06B
ALTAltimmune Inc375.41M
SGMTSagimet Biosciences Inc802.60M
VKTXViking Therapeutics Inc3.63B
GALTGalectin Therapeutics Inc331.79M
GYREGyre Therapeutics Inc491.27M
GPCRStructure Therapeutics Inc ADR1.49B
AVLNAvalyn Pharma Inc1.40B
MTVAMetaVia Inc9.49M
PLRXPliant Therapeutics Inc48.15M

Held by

AUM
TickerCompanyAUM
SURISimplify Propel Opportunities ETFAUM: 74.30M
MEDIHarbor Health Care ETFAUM: 44.19M
APIEActivePassive International Equity ETFAUM: 1.13B

News

latest 14 of 200

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026S12026-09-28-0.284-0.422-0.2850.022.885
2025S22026-03-30-1.000-0.548-1.0761.535.156
2025S12025-09-29-1.900-0.624-1.7655.225.244
2024S22025-03-26-2.162-0.750-2.31510.536.403
2024S12024-09-25-1.050-1.323-1.0200.050.001
2024Q12024-05-21-0.480-0.520--1.501
2023S22024-03-27-1.174-0.843-1.21215.8115.302
2023Q32023-11-21-0.980-0.500-0.001.501
2023Q22023-09-28-1.387-0.878-2.011.042
2023Q12023-05-16-0.290-0.230-0.001.501
2022Q42023-03-290.080-0.090-20.0713.001
2026S2---0.329--4.189
2027S1---0.349--1.665
2027S2---0.351--7.065
2028S1---0.247--46.021
2028S2---0.258--56.251

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2019FY-1.444-1.676-1.4387.896.60
2020FY-1.179-1.225-1.1310.444.85
2021FY-1.353-1.904-1.4987.516.18
2022FY-1.430-1.485-1.37613.2916.90
2023FY-2.624-2.121-2.63218.8814.71
2024FY-3.326-1.455-3.3339.938.96
2025FY-2.189-1.642-2.1135.179.63
2026FY--0.693--4.21
2027FY--0.564--14.00
2028FY--0.225--162.34
2029FY--0.036--370.41
2030FY-0.582--718.08

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026S2S2026-11-049034.180.0011.36
2026S2S2026-10-228034.710.0011.36
2026S2S2026-10-128134.710.0011.36
2026S2S2026-10-018134.730.0011.36
2026S2S2026-09-288134.730.0011.36
2026S2S2026-09-144106.020.0011.50
2026S2S2026-09-034106.020.0011.50
2026S2S2026-08-195104.820.0011.50
2026S2S2026-08-125114.820.0011.50
2026S2S2026-08-055114.800.0011.50
2026S2S2026-07-305024.790.0011.50
2026S2S2026-07-245014.800.0011.56
2026S2S2026-07-165014.810.0011.56
2026S2S2026-07-104013.460.0011.56

Estimate history

EPS, annual-1.387-1.931-1.438-1.131-1.498-1.376-2.632-3.333-2.14
Period201720182019202020212022202320242025
EPS, quarterly
Period
Sales, annual5.4113.7727.8330.4244.95712.818.8959.9495.059
Period201720182019202020212022202320242025
Sales, quarterly
Period
Shares, annual16.40122.20526.77938.61540.87442.13452.11695.662193.237
Period201720182019202020212022202320242025
Shares, quarterly
Period

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue0.065.069.9518.8912.804.960.427.833.77
Cost of Goods Sold Incl. D&A3.053.293.882.73-----
Gross Profit-2.991.776.0716.16-----
Selling, General and Administrative Excl. Other172.68156.06113.67133.3078.0769.4036.2243.2843.60
Research and Development100.4295.2495.17116.4362.0156.3826.0936.6336.42
Other Operating Expense-0.17-0.430.00-0.37-1.11-0.23-0.840.06-
Operating Income-175.49-153.86-107.60-116.77-65.93-65.30-36.10-37.14-40.95
Interest Expense44.7337.9513.245.650.790.170.080.020.24
Unusual Expense105.64212.3885.890.470.551.891.191.59-
Net Income Before Taxes-290.50-401.82-203.87-122.31-63.22-63.05-43.79-38.63-45.07
Income Taxes-1.59-2.54-4.95-5.11-6.18-4.38-5.46-4.80-5.41
Consolidated Net Income-288.92-399.67-199.26-119.38-57.04-58.67-38.32-33.82-39.66
Net Income From Continuing Operations-288.92-399.67-199.26-119.38-57.04-58.67-38.32-33.82-39.66
Net Income-288.92-399.67-199.26-119.38-57.04-58.67-38.32-33.82-39.66
EPS (Recurring)-0.79-1.34-2.33-2.63-1.37-1.46-1.11-1.39-1.93
EPS (Basic, Before Extraordinaries)-1.37-2.14-3.33-2.63-1.38-1.50-1.13-1.44-1.93
EPS (Diluted)-1.37-2.14-3.33-2.63-1.38-1.50-1.13-1.44-1.93
EBITDA-172.44-150.57-103.72-114.04-64.16-64.21-34.95-35.51-39.83
Non-Operating Income (Expense)35.372.372.860.574.054.32-6.410.13-3.87
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense25.5621.572.853.151.711.811.071.090.66
Price To Sales Ratio18,094.87171.6912.8610.8414.44107.931,158.26--
Gross Margin-5,232.8135.0760.9985.54-----
Operating Margin-307,068.32-3,040.98-1,081.49-618.00-515.05-1,317.31-8,513.72-474.22-1,085.74
Net Margin-505,545.60-7,899.58-2,002.74-631.84-445.64-1,183.48-9,037.38-431.81-1,051.52
Shares Outstanding236.28193.2495.6652.1242.1340.8738.6126.7822.21
Market Capitalization944.46944.46204.34235.35187.92558.12555.87529.04-

Income statement, quarterly

Currency USD, millions
Metric2026S12025S22025S12024S22024S12023S22023S12022S2
Total Revenue0.020.034.869.910.0416.852.0512.28
Cost of Goods Sold Incl. D&A1.641.411.861.882.001.471.26-
Gross Profit-1.62-1.373.008.04-1.9615.380.79-
Selling, General and Administrative Excl. Other81.3191.3765.4656.0957.5768.0365.2838.50
Research and Development52.5247.9047.3046.4448.7459.1757.2730.13
Other Operating Expense-0.180.00-0.420.000.000.80-1.17-0.66
Operating Income-82.75-92.75-62.04-48.06-59.53-53.46-63.31-26.56
Interest Expense16.8827.8510.647.555.693.532.120.51
Unusual Expense14.3891.26120.0791.09-9.192.18-1.710.50
Net Income Before Taxes-82.03-208.47-193.63-148.41-55.53-58.66-63.65-27.83
Income Taxes-0.86-0.73-1.78-2.23-2.71-1.18-3.93-2.69
Consolidated Net Income-81.03-207.89-192.10-146.34-52.99-59.67-59.72-25.14
Net Income From Continuing Operations-81.03-207.89-192.10-146.34-52.99-59.67-59.72-25.14
Net Income-81.03-207.89-192.10-146.34-52.99-59.67-59.72-25.14
EPS (Recurring)-0.26-0.75-0.99-1.31-1.14-1.18-1.45-0.59
EPS (Basic, Before Extraordinaries)-0.30-1.08-1.76-2.31-1.02-1.21-1.42-0.60
EPS (Diluted)-0.30-1.08-1.76-2.31-1.02-1.21-1.42-0.60
EBITDA-81.11-91.34-60.18-46.18-57.53-51.98-62.05-25.56
Non-Operating Income (Expense)31.983.39-0.88-1.710.500.500.08-0.26
Stock Option Compensation Expense10.2815.286.561.031.811.531.620.40
Price To Sales Ratio18,094.87183.4423.5013.599.2011.7611.8515.19
Gross Margin-6,929.96-4,062.1161.7481.06-4,421.9791.2638.66-
Operating Margin-354,677.83-274,226.89-1,275.30-484.82-134,341.97-317.26-3,082.17-216.36
Net Margin-347,332.88-614,682.02-3,948.85-1,476.28-119,583.37-354.12-2,907.36-204.82
Shares Outstanding236.28193.24139.1595.6652.4852.1242.1342.13
Market Capitalization944.46888.11443.75204.34156.59235.35170.22187.92

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments116.6499.9929.7392.5798.43129.3140.2364.8170.91
Short Term Receivables10.7112.5917.359.9713.1816.5413.6415.268.24
Inventories0.000.000.460.400.450.390.430.470.57
Other Current Assets159.152.535.2210.3018.5215.220.561.351.00
Total Current Assets286.50115.1152.77113.24130.57161.4754.8681.8980.72
Net Property, Plant & Equipment3.505.1810.087.883.634.024.184.875.42
Total Investments and Advances0.621.181.570.000.000.000.000.000.00
Long-Term Note Receivable-0.000.000.07-0.002.622.590.40
Intangible Assets0.210.050.600.610.881.141.381.762.17
Deferred Tax Assets0.220.22-----0.000.30
Other Assets1.371.0811.361.712.782.090.900.120.29
Total Assets292.42122.8376.37123.50137.85168.7263.9491.2489.30
Short Term Debt Incl. Current Port. of LT Debt37.436.005.776.241.460.020.130.170.31
Accounts Payable30.5634.0341.6220.6616.618.478.419.576.46
Income Tax Payable---2.271.000.920.750.660.52
Other Current Liabilities22.8984.998.013.596.937.606.286.843.52
Total Current Liabilities90.88125.0255.4132.7725.9917.0215.5617.2410.82
Long Term Debt32.3650.1835.5530.5910.0512.280.000.080.26
Provision for Risks Charges0.891.821.721.321.634.611.911.591.61
Other Liabilities202.4256.6019.5510.600.000.000.001.912.28
Total Liabilities326.54233.62112.2275.2737.6633.9017.4820.8214.98
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.000.00
Common Equity-34.12-110.79-35.8548.23100.19134.8146.4670.4174.32
Total Shareholders Equity-34.12-110.79-35.8548.23100.19134.8146.4670.4174.32
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity-34.12-110.79-35.8548.23100.19134.8146.4670.4174.32
Total Liabilities & Stockholders Equity292.42122.8376.37123.50137.85168.7263.9491.2489.30
Book Value Per Share-0.18-1.16-0.691.142.453.491.743.174.53
Tangible Book Value Per Share-0.18-1.16-0.701.132.433.461.683.094.40
Full-Time Employees771191231131059488113107
Price to Book Ratio13.84-1.32-21.912.595.574.159.08--
Return on Assets-192.50-200.06-119.46-43.65-38.27-32.95-43.59-43.94-30.57
Return on Equity---1,928.18-76.86-49.93-42.28-57.88-53.86-38.44
Return on Invested Capital----72.36-53.22-26.05-72.79-56.26-28.86
Quick Ratio3.150.920.943.445.019.473.504.727.41
Current Ratio3.150.920.953.465.029.493.534.757.46

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-301.95-399.67-199.26-119.38-57.04-58.67-38.32-33.82-39.66
Depreciation0.723.293.882.731.771.102.151.772.73
Other Funds (Non Cash)149.58270.2094.854.06-1.68-9.293.551.12-4.58
Funds from Operations-151.65-126.19-100.53-112.59-56.96-66.86-32.62-30.93-41.50
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital20.127.547.5824.359.7410.56-2.25-0.861.15
Income Taxes Payable-5.555.775.643.739.41---
Cash from Operating Activities-131.53-118.65-92.95-88.23-47.22-56.30-34.87-31.79-40.36
Capital Expenditures-0.42-0.28-0.36-0.58-0.59-0.63-0.33-0.15-0.65
Net Assets From Acquisitions0.000.000.000.000.000.000.000.00-
Sale of Fixed Assets and Businesses0.000.000.000.140.040.110.000.000.00
Purchase or Sale of Investments-53.38-150.039.74-8.97-0.00-0.06-0.65-0.780.15
Purchase of Investments-128.02-150.030.00-8.97-0.00-0.06-0.65-0.780.00
Sale Or Maturity of Investments74.640.009.740.000.000.000.00-0.15
Other Uses0.000.000.000.000.00-1.54-8.770.000.00
Other Sources0.000.000.081.069.870.000.000.000.00
Cash from Investing Activities-53.80-150.319.46-8.369.32-2.12-9.75-0.92-0.50
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock222.78279.34135.9335.879.2830.11116.039.6938.37
Repurchase of Common Pref Stock-58.680.000.000.000.000.000.000.000.00
Sale of Common Pref Stock281.45279.34135.9335.879.2830.11116.039.6938.37
Proceedsfrom Stock Options277.14213.65135.9335.879.2830.05116.039.6938.37
Issuance or Reduction of Debt, Net15.84-3.6924.13-2.6930.66-0.0211.31-0.16-0.31
Net Financing Active Other Cash Flow0.000.000.000.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.000.000.000.00
Cash from Financing Activities237.49272.59157.4931.4439.1730.08127.319.3838.07
Exchange Rate Effect1.13-0.531.340.48-1.085.72-3.06--
Net Change in Cash53.283.1075.34-64.670.19-22.6279.62-23.34-2.78
Free Cash Flow-131.95-118.93-93.31-88.82-47.81-56.93-35.20-31.91-41.00
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.000.00
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026S12025S22025S12024S22024S12023S2
Cash & Short Term Investments189.93116.64143.3099.9910.8829.73
Short Term Receivables11.9110.7126.7512.5911.5117.35
Inventories0.000.000.000.000.420.46
Other Current Assets79.37159.1532.292.537.545.22
Total Current Assets281.21286.50202.34115.1130.3552.77
Net Property, Plant & Equipment2.703.504.685.188.5510.08
Total Investments and Advances0.600.620.981.181.211.57
Intangible Assets0.350.210.100.050.480.60
Deferred Tax Assets0.230.220.230.220.23-
Other Assets2.111.371.231.081.1211.36
Total Assets287.21292.42209.55122.8341.9576.37
Short Term Debt Incl. Current Port. of LT Debt15.2237.436.496.006.145.77
Accounts Payable39.4830.5640.7434.0339.2141.62
Other Current Liabilities19.1422.8921.3984.996.268.01
Total Current Liabilities73.8490.8868.62125.0251.6055.41
Long Term Debt60.9932.3660.5750.1850.2135.55
Other Liabilities84.14202.4290.2956.6023.5119.55
Total Liabilities219.75326.54220.53233.62126.99112.22
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity67.46-34.12-10.97-110.79-85.04-35.85
Total Shareholders Equity67.46-34.12-10.97-110.79-85.04-35.85
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity67.46-34.12-10.97-110.79-85.04-35.85
Total Liabilities & Stockholders Equity287.21292.42209.56122.8341.9576.37
Book Value Per Share0.29-0.18-0.08-1.16-1.62-0.69
Tangible Book Value Per Share0.28-0.18-0.08-1.16-1.63-0.70
Price to Book Ratio13.84-58.98-2.75-1.32-4.35-21.91
Return on Assets-116.32-192.65-269.13-200.13-189.52-119.46
Return on Equity-1,022.99-----1,928.29
Return on Invested Capital-63.09--387.30---
Quick Ratio3.813.152.950.920.580.94
Current Ratio3.813.152.950.920.590.95

Cash flow, quarterly

Currency USD, millions
Metric2026S12025S22025S12024S22024S12023S2
Net Income-81.03-220.92-192.10-146.42-52.99-59.73
Depreciation1.81-1.094.491.852.031.50
Other Funds (Non Cash)0.90148.67130.5499.01-4.094.97
Funds from Operations-78.32-73.34-57.06-45.55-55.06-53.26
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital10.539.59-1.804.782.8113.85
Income Taxes Payable-----0.01
Cash from Operating Activities-67.78-63.75-58.86-40.77-52.25-39.41
Capital Expenditures-0.20-0.23-0.06-0.08-0.28-0.34
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.00-0.100.100.00
Purchase or Sale of Investments74.64-128.02-27.020.019.740.31
Purchase of Investments0.00-128.02-27.020.000.000.31
Sale Or Maturity of Investments74.640.000.000.019.740.00
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.08-0.02
Cash from Investing Activities74.44-128.24-27.09-0.179.63-0.04
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock52.13170.64118.02136.030.0135.89
Repurchase of Common Pref Stock-58.680.000.000.000.000.00
Sale of Common Pref Stock110.81170.64118.02136.030.0135.89
Proceedsfrom Stock Options110.81166.3354.45136.030.0135.89
Issuance or Reduction of Debt, Net19.65-1.85-1.96-1.5025.65-1.12
Net Financing Active Other Cash Flow0.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities70.42167.07114.62133.2124.3933.79
Exchange Rate Effect0.860.27-0.811.240.100.92
Net Change in Cash77.94-24.6627.8693.52-18.13-4.74
Free Cash Flow-67.98-63.98-58.92-40.85-52.53-39.74

Revenue breakdown

Total Pharmaceutical Preparations revenue2024: 9.95M 2025: 5.06M
China2024: 9.88M 2025: 5.06M
France2024: 74.66K

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-304.68%10.3M221.0M1.91M
2026-10-153.71%8.2M220.0M1.54M
2026-09-303.79%8.3M220.0M1.33M
2026-09-152.22%4.9M218.4M1.14M
2026-08-311.69%3.7M218.4M1.08M
2026-08-141.18%2.6M218.4M1.00M
2026-07-310.99%2.2M221.4M952.96K
2026-07-150.80%1.8M223.2M848.60K
2026-06-300.64%1.4M221.5M655.34K
2026-06-150.49%1.1M221.5M443.61K
2026-05-290.35%0.7M195.8M318.46K
2026-05-150.31%0.6M195.8M345.69K
2026-04-300.34%0.6M186.7M373.50K
2026-04-150.23%0.4M186.7M446.51K
2026-03-310.23%0.4M192.4M442.80K
2026-03-130.23%0.4M192.4M438.28K
2026-02-270.29%0.5M192.4M418.04K
2026-02-130.36%0.7M191.2M389.95K
2026-01-300.32%0.6M195.7M380.28K
2026-01-150.09%0.2M182.1M356.82K

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call2.501.352.301.757.56236.000.000.835-0.0560.002
call5.000.450.900.724.9142,9841250.538-0.0690.002
call7.500.200.600.255.4841,65515.000.380-0.0740.002
call10.000.000.750.506.5352510.000.349-0.0850.002
put2.500.200.600.256.3452,04814.00-0.165-0.0560.002
put5.001.302.351.756.82935.004.00-0.462-0.0680.002
put7.503.404.804.508.39718.000.00-0.620-0.0730.002
put10.005.508.506.6014.91119.000.00-0.651-0.0840.002

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-10-27SCHEDULE 13G/ASEC
2026-10-066-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-10-06SEC
2026-09-286-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-06-30SEC
2026-09-036-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-09-02SEC
2026-09-016-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-08-31SEC
2026-07-306-K/A2026-07-30SEC
2026-07-296-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-07-29SEC
2026-07-096-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-07-09SEC
2026-07-066-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-07-02SEC
2026-06-126-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-06-12SEC
2026-06-126-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-06-12SEC
2026-06-096-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-06-09SEC
2026-06-036-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-06-03SEC
2026-06-036-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-06-02SEC
2026-06-02424B5SEC
2026-06-02FWPFiling under Securities Act Rule 163/433 of free writing prospectuses.SEC
2026-06-02F-3ASRAutomatic shelf registration statement of securities of well-known seasoned issuersSEC
2026-05-266-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-05-26SEC
2026-05-226-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-05-22SEC
2026-05-15SCHEDULE 13G/ASEC
2026-04-226-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-04-22SEC
2026-04-0820-FRegistration statement under Section 12 of the Securities Exchange Act of 1934 or an annual or transition report filed under Section 13(a) or 15(d) of the Exchange Act for a foreign private issuer.2025-12-31SEC
2026-04-01SCHEDULE 13D/ASEC
2026-03-306-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-03-30SEC
2026-02-17SCHEDULE 13G/ASEC
2026-02-17SCHEDULE 13G/ASEC
2026-02-176-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-02-17SEC
2026-02-17SCHEDULE 13G/ASEC
2026-02-13SCHEDULE 13G/ASEC
2026-01-30SCHEDULE 13GSEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
Caligan Partners LP3.46%
Samsara BioCapital, LLC2.67%
Nantahala Capital Management, LLC2.27%
FMR LLC2.01%
Paradigm Biocapital Advisors LP1.69%
Andera Partners1.54%
ADAR1 Capital Management, LLC1.53%
MILLENNIUM MANAGEMENT LLC1.49%
Aberdeen Group plc1.33%
Trails Edge Capital Partners, LP1.13%

Funds

Fund% owned
abrdn World Healthcare Fund0.51%
abrdn Life Sciences Investors0.46%
Franklin Biotechnology Discovery Fund0.43%
Fidelity Advisor Biotechnology Fund0.29%
Simplify Propel Opportunities ETF0.13%
Strategic Advisers Fidelity U.S. Total Stock Fund0.09%
Fidelity Small Cap Stock Fund0.07%
Artisan International Small-Mid Fund0.06%
Fidelity Series Small Cap Core Fund0.06%
Tax-Managed U.S. Mid & Small Cap Fund0.03%

OakChart. IVA. Cached 15 minutes.

Some panels did not load: insider.